跳至主要内容
临床试验/NCT02967861
NCT02967861已完成早期 1 期

Effect of Pranayama on Peroxisome Proliferator-activated Receptor Gamma, Nuclear Factor Kappa B and Red Complex Microorganisms in Patients With Chronic Periodontitis

Meenakshi Ammal Dental College and Hospital0 个研究点目标入组 60 人开始时间: 2016年1月1日最近更新:
适应症

试验速览

阶段
早期 1 期
状态
已完成
发起方
入组人数
60
主要终点
Clinical efficacy of pranayama in chronic periodontitis patients from baseline to 3 months

研究概览

简要总结

The objective of the study was to evaluate the levels of Peroxisome proliferator-activated receptor gamma (PPAR-γ), Nuclear factor-kappa B (NF-kB) and the presence of red complex microorganisms (RCM) such as Treponema denticola (T.d), Porphyromonas gingivalis (P.g) and Tannerella forsythia (T.f) in the subgingival tissues of chronic periodontitis subjects before and after intervention with pranayama as an adjunct to scaling and root planing.

详细描述

Sixty chronic periodontitis subjects were selected out of which 30 subjects (control group) were treated with scaling and root planing (SRP) and 30 subjects (pranayama group) also underwent SRP and pranayama for 3 months. Clinical parameters were recorded and the presence of PPAR-γ, NF-kB and RCM were assessed at baseline and after 3 months

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Investigator)

入排标准

年龄范围
30 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • presence of at least 20 teeth
  • Probing pocket depth ≥ 5 mm

排除标准

  • aggressive periodontitis
  • systemic disorders
  • pregnant & lactating females
  • smokers & alcoholics
  • immunocompromised individuals

结局指标

主要结局

Clinical efficacy of pranayama in chronic periodontitis patients from baseline to 3 months

时间窗: 3 months

Clinical attachment level is measured using Williams periodontal probe in millimeters with the criteria of 1 to 2 mm for slight periodontitis, 3 to 4 mm for moderate periodontits and greater or equal to 5 mm for severe periodontitis.

次要结局

  • Efficacy of pranayama on perosxisome proliferator-activated receptor (PPAR)-γ in chronic periodontitis patients(3 months)
  • Microbiological efficacy of pranayama in chronic periodontitis patients from baseline to 3 months(3 months)
  • Efficacy of pranayama on nuclear factor-kappa B (NF-kB) in chronic periodontitis patients(3 months)

研究者

发起方
Meenakshi Ammal Dental College and Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr.Jaideep Mahendra

Professor

Meenakshi Ammal Dental College and Hospital

相似试验

进行中(未招募)
不适用
The effect of peroxisome proliferator activator receptor ? agonist pre-treatment on pegylated interferon-a2a and ribavirin efficacy in hepatitis C patients, previously resistant to treatment with pegylated interferon and ribavirin - a randomized-controlled trial - - HEPAR studyChronic hepatitis C infectionMedDRA version: 9.1Level: LLTClassification code 10008912Term: Chronic hepatitis C
EUCTR2007-007075-16-NLVU university medical center50
撤回
不适用
The effect of peroxisome proliferator activator receptor * agonist pre-treatment on pegylated interferon-*2a and ribavirin efficacy in hepatitis C patients, previously resistant to treatment with pegylated interferon and ribavirin - a randomized-controlled trialViral liver disease1001965410047438Hepatitis C
NL-OMON31787Vrije Universiteit Medisch Centrum50
进行中(未招募)
不适用
Effects of the activation of PPARs in the orphan hepatic disease primary biliary cirrhosisp to 67% of PBC patients have an incomplete biochemical response to UDCA and remain at increased risk for progression to cirrhosis and liver-related death. In this study we will prospectively examine the therapeutic effects of bezafibrate (a pan-agonist activating PPARalpha/delta/gamma) in patients with early-stage PBC with a specific focus on improvement of liver functions, inflammation, lipid profile, oxidative status and endothelial function.
EUCTR2011-004681-15-ATMedizinische Universität Graz
已完成
4 期
Peroxisome Proliferator-Activated Receptor-Gamma Activation in Peritoneal Dialysis PatientsEnd-stage Renal Disease
NCT00745225The University of Hong Kong160
进行中(未招募)
1 期
The use of Peroxisome Proliferator Activator Receptor Agonists in the management of Androgen Independent Prostate Cancer - PPAR
EUCTR2006-001398-44-GBBarts and The London NHS Trust49